This trial studies the effect of pegloticase in reducing uric acid levels in patients with hyperuricemia (high blood levels of uric acid) caused by tumor lysis syndrome. Tumor lysis syndrome occurs when the breakdown products of cancer cells, such as uric acid, enter the blood stream. High levels of uric acid in blood may cause kidney damage and reduce kidney function. The goal of this trial is to learn if pegloticase may lower uric acid levels in blood when given to cancer patients with hyperuricemia caused by tumor lysis syndrome.

Start Date05 Apr 2022

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NL-OMON27662 / SuspendedNot Applicable

Treatment of severe gout patients with rasburicase

Start Date03 May 2021

Sponsor / Collaborator-

100 Clinical Results associated with Rasburicase

100 Translational Medicine associated with Rasburicase

100 Patents (Medical) associated with Rasburicase

1,063

Literatures (Medical) associated with Rasburicase

26 Nov 2024·Blood Advances

Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax

Article

Author: Kabel, Charlene ; Valtis, Yannis K. ; Thompson, Meghan C. ; Nemirovsky, David ; Geyer, Mark B. ; Derkach, Andriy ; Roeker, Lindsey E. ; Ortiz, Ricardo ; Sharan, Saumya

AbstractVenetoclax is a B-cell lymphoma 2 inhibitor used in chronic lymphocytic leukemia (CLL), which can cause tumor lysis syndrome (TLS). We aimed to determine the incidence of, and risk factors for, TLS among patients with CLL/small lymphocytic lymphoma who received treatment with venetoclax at our institution from 1 January 2016 to 31 December 2020. We included 616 venetoclax escalations among 136 patients with CLL. Overall, 74 patients (54%) underwent escalation exclusively outpatient, 35 (26%) had at least 1 planned hospitalization, and 27 (20%) were escalated exclusively inpatient. During venetoclax initiation, 86% of patients received allopurinol, 71% intravenous hydration, 18% phosphate binders, and 10% prophylactic rasburicase. Among the entire cohort, 7 patients (5.1%) developed laboratory TLS by modified Cairo Bishop criteria and none developed clinical TLS. Incidence of laboratory TLS was 15% for those escalated exclusively inpatient, 2.9% for those with any prophylactic hospitalization, and 2.7% for those escalated exclusively outpatient. Those who developed TLS were more likely to have higher TLS risk, and no additional risk factors were identified. In this single institution retrospective cohort study, laboratory TLS was observed, although clinical TLS was not. Prophylactic measures, including use of IV hydration, may have contributed to low rates of observed TLS in the outpatient setting.

01 Nov 2024·Free Radical Biology and Medicine

Unconjugated bilirubin promotes uric acid restoration by activating hepatic AMPK pathway

Article

Author: Chen, Binxin ; Lu, Shuanghui ; Jiang, Huidi ; Zhang, Nanxin ; Lin, Nengming ; Zhou, Hui ; Chen, Xiaojing ; Li, Ping ; Li, Qi ; Jiang, Ting ; Zhang, Yingqiong ; Luo, Jun ; Zhang, Bichen ; Bai, Mengru ; Chen, Yujia ; Gao, Yue

Hyperuricemia and its development to gout have reached epidemic proportions. Systemic hyperuricemia is facilitated by elevated activity of xanthine oxidase (XO), the sole source of uric acid in mammals. Here, we aim to investigate the role of bilirubin in maintaining circulating uric acid homeostasis. We observed serum bilirubin concentrations were inversely correlated with uric acid levels in humans with new-onset hyperuricemia and advanced gout in a clinical cohort consisting of 891 participants. We confirmed that bilirubin biosynthesis impairment recapitulated traits of hyperuricemia symptoms, exemplified by raised circulating uric acid levels and accumulated hepatic XO, and exacerbated mouse hyperuricemia development. Bilirubin administration significantly decreased circulating uric acid levels in hyperuricemia-inducing (HUA) mice receiving potassium oxonate (a uricase inhibitor) or fed with a high fructose diet. Finally, we proved that bilirubin ameliorated mouse hyperuricemia by increasing hepatic autophagy, restoring antioxidant defense and normalizing mitochondrial function in a manner dependent on AMPK pathway. Hepatocyte-specific AMPKα knockdown via adeno-associated virus (AAV) 8-TBG-mediated gene delivery compromised the efficacy of bilirubin in HUA mice. Our study demonstrates the deficiency of bilirubin in hyperuricemia progression, and the protective effects exerted by bilirubin against mouse hyperuricemia development, which may potentiate clinical management of hyperuricemia.

01 Oct 2024·Nature Nanotechnology

Multimodal smart systems reprogramme macrophages and remove urate to treat gouty arthritis

Article

Author: Zhao, Dezhang ; Liu, Yingju ; Pu, Daojun ; He, Dan ; Zhang, Jingqing ; Liu, Yuying ; Xu, Jingxin ; Wu, Mingjun ; Tan, Qunyou ; Zhang, Ling ; Yang, Jie ; Yan, Xiong

Gouty arthritis is a chronic and progressive disease characterized by high urate levels in the joints and by an inflammatory immune microenvironment. Clinical data indicate that urate reduction therapy or anti-inflammatory therapy alone often fails to deliver satisfactory outcomes. Here we have developed a smart biomimetic nanosystem featuring a 'shell' composed of a fusion membrane derived from M2 macrophages and exosomes, which encapsulates liposomes loaded with a combination of uricase, platinum-in-hyaluronan/polydopamine nanozyme and resveratrol. The nanosystem targets inflamed joints and promotes the accumulation of anti-inflammatory macrophages locally, while the uricase and the nanozyme reduce the levels of urate within the joints. Additionally, site-directed near-infrared irradiation provides localized mild thermotherapy through the action of platinum and polydopamine, initiating heat-induced tissue repair. Combined use of these components synergistically enhances overall outcomes, resulting in faster recovery of the damaged joint tissue.

News (Medical) associated with Rasburicase

13 Jun 2024

·www.prnewswire.com

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

Event will take place on Wednesday, June 26, 2024 in New York CARMIEL, Israel, June 13, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will host an in-person investor day at the Lotte Palace New York Hotel in New York on Wednesday, June 26, 2024 at 8:30 a.m. Eastern Daylight Time (EDT). The investor day will feature presentations by the following key opinion leaders: Aleš Linhart, DSc, FESC (Charles University, Prague), who will discuss the treatment landscape for Fabry disease and perspectives on Elfabrio® (pegunigalsidase alfa), a plant cell-expressed PEGylated recombinant α-Galactosidase-A enzyme approved for adult patients with Fabry disease. Naomi Schlesinger, MD (University of Utah), who will discuss the current treatment landscape for uncontrolled gout and top-line results from the First-in-Human Phase I single ascending dose clinical trial of PRX-115, a plant cell-expressed recombinant PEGylated uricase. In addition, the event will include a corporate overview and strategy presentation by Dror Bashan, Protalix's President and Chief Executive Officer. A live question and answer session will follow the formal presentations. To register for the event, please click here. About Aleš Linhart, DSc, FESC Aleš Linhart, DSc, FESC is currently heading the Department of Cardiovascular Medicine of the First Medical Faculty and General University in Prague, Czech Republic and serves as vice-dean for international affairs of the First Faculty of Medicine of Charles University in Prague. He obtained his MD degree at Charles University in Prague, received his training in cardiology and vascular medicine at General University Hospital in Prague and Broussais Hospital in Paris, France. In 2004 he was appointed professor at Charles University in Prague. His research focuses mainly on Fabry disease, metabolic cardiomyopathies, noninvasive cardiac imaging, and atherosclerosis. He is member of several scientific societies, namely Czech and European Society of Cardiology (ESC). He served as the chairman of the Working Group on Myocardial and Pericardial Diseases of the ESC and is the immediate past president of the Czech Society of Cardiology. He authored or co-authored more than 450 scientific peer-reviewed papers, 85 book chapters, and three monographs. About Naomi Schlesinger, MD Naomi Schlesinger, MD is the Harold J, Ardella T, and Helen T Stevenson Presidential Endowed Chair of Rheumatology, Professor and Chief Division of Rheumatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT. She is a previous Chief of the Division of Rheumatology at Rutgers-Robert Wood Johnson Medical School and Director of Rutgers Robert Wood Johnson Medical School Gout Center. Dr. Schlesinger is a previous President of the NJ Rheumatology Association and current President of the Utah Rheumatology Association and was the recipient of the 2015 Rheumatologist of The Year award by the Arthritis Foundation - NJ Chapter. Dr. Schlesinger is a noted authority in the field of gout, having published many papers regarding the diagnosis, treatment, and better understanding of the pathogenesis of gout. Dr. Schlesinger's research has won recognition, including the work titled: Efficacy of canakinumab (ACZ885), a fully human anti-Interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy, which was selected as one of the five highest-ranking abstracts that will likely shape our treatment paradigms for years to come in the 2010 ACR/ ARHP Annual Scientific Meeting and the work titled: Erectile dysfunction is common among gout patients, which was selected (one of 13) for inclusion in the official 2014 EULAR Press Conference from over 4000 abstracts. Other pioneering work includes the treatment of gout flares with topical ice, seasonality of gout, diagnosing gout using ultrasound, understanding the pathogenesis of bone erosions in gout, and the importance of anti-inflammatory treatment in gout. Dr. Schlesinger serves as the American College of Rheumatology (ACR) abstract Co-Chair on metabolic and crystal arthropathies, a member of the ACR Global Engagement Special Committee (GESC), and a member of the ACR Annual Meeting Planning Committee (AMPC). She is a Co-Director of the International Gout and Hyperuricemia Center, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. She serves as a consultant to pharmaceutical companies in the field of gout. About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Investor Contact Mike Moyer, Managing Director LifeSci Advisors 617 308 4306 [email protected] Logo: SOURCE Protalix BioTherapeutics, Inc.

Phase 1Drug Approval

30 Oct 2023

·www.prnewswire.com

Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023

Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel, Oct. 30, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the third quarter ended September 30, 2023 and provide a business update on Monday, November 6, 2023. Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date: Monday, November 6, 2023 Time: 8:30 a.m. Eastern Standard Time (EST) Toll Free: 1-877-423-9813 Israeli Toll Free: 1-809-406 247 International: 1-201-689-8573 Conference ID: 13741587 Call me™: The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away. Webcast Details: The conference will be webcast live from the Company's website and will be available via the following links: Company Link: Webcast Link: Conference ID: 13741587 Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link. About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Investor Contact Chuck Padala, Managing Director LifeSci Advisors +1-646-627-8390 [email protected] Logo - SOURCE Protalix BioTherapeutics, Inc.

Drug ApprovalFinancial Statement

09 Oct 2023

·www.prnewswire.com

Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel

CARMIEL, Israel, Oct. 9, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today issued the following statement by Dror Bashan, Protalix's President and Chief Executive Officer, regarding the current security situation in Israel. "The Protalix family is horrified by the unconscionable events in Israel over the past weekend which are currently ongoing and the scope of which is yet to be determined. On a personal level, we are heartbroken and pray for the victims as well as their families, friends and other loved ones. At Protalix, we are dedicated to helping our own families, friends and colleagues cope with this devastating situation and to provide them with any support they need. At the same time, we wish to reaffirm our employees, partners and stockholders that Protalix's operations have not been adversely affected by this situation despite our personal grieving. Hostilities have not taken place where Protalix's facilities are located and we do not anticipate any disruption to the supply of Elfabrio® or Elelyso®. We thank all of our partners and stockholders that have reached out to express their support and best wishes, and are grateful for their continued confidence in Protalix." About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Forward-Looking Statements To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms "expect," "anticipate," "believe," "estimate," "project," "may," "plan," "will," "would," "should" and "intend," and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on Protalix's current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk, and various factors may cause differences between our expectations and actual results as discussed in greater detail in our filings with the Securities and Exchange Commission. Factors that might cause material differences include, among others, the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers and other factors described in our filings with the U.S. Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law. Investor Contact Chuck Padala, Managing Director LifeSci Advisors +1-646-627-8390 [email protected] Logo - SOURCE Protalix BioTherapeutics, Inc.

Drug Approval

100 Deals associated with Rasburicase

External Link

KEGG	Wiki	ATC	Drug Bank
D05704	Rasburicase	V03AF07	DB00049

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperuricemia	IS	Sanofi Winthrop Industrie SA	23 Feb 2001
Hyperuricemia	NO	Sanofi Winthrop Industrie SA	23 Feb 2001
Hyperuricemia	EU	Sanofi Winthrop Industrie SA	23 Feb 2001
Hyperuricemia	LI	Sanofi Winthrop Industrie SA	23 Feb 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Leukemia	Phase 2	US	Sanofi	01 Apr 2004
Lymphoma	Phase 2	US	Sanofi	01 Apr 2004
Solid tumor	Phase 2	US	Sanofi	01 Apr 2004
Tumor Lysis Syndrome	Phase 2	US	Sanofi	01 Apr 2004
Hematologic Neoplasms	Preclinical	CN	Sanofi	01 Oct 2007
Tumor Lysis Syndrome	Preclinical	US	Sanofi	01 Apr 2004
Aggressive Non-Hodgkin Lymphoma	Preclinical	FR	Sanofi	01 Jul 2002
Aggressive Non-Hodgkin Lymphoma	Preclinical	IT	Sanofi	01 Jul 2002
Aggressive Non-Hodgkin Lymphoma	Preclinical	BE	Sanofi	01 Jul 2002
Aggressive Non-Hodgkin Lymphoma	Preclinical	DE	Sanofi	01 Jul 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2023	Not Applicable	Neoplasms	715	Rasburicase	ldjnbpbxby(nqlvqkjecl) = czqwcxodda pwmlpmojzq (uunwkryrwx ) View more	-	23 Oct 2023
ESMO2023	Not Applicable	Neoplasms	715	Allopurinol	ldjnbpbxby(nqlvqkjecl) = euhkdnxpuy pwmlpmojzq (uunwkryrwx ) View more	-	23 Oct 2023
ERA2023	Not Applicable	Cardio-Renal Syndrome	23	Rasburicase	(jrmojzpkev) = oeybsudeqo tyeckwzlly (xdsbsgltvc ) View more	-	15 Jun 2023
EHA2020	Not Applicable	Tumor Lysis Syndrome \| Leukemia \| Lymphoma	55	Low dose Rasburicase	vzdkndebhr(jiptevfkvz) = jseqftopac wyxtyovxgi (jgiwyqkfin )	Positive	14 May 2020
NCT01200485 (CTgov)	Phase 2	Tumor Lysis Syndrome \| Leukemia \| Lymphoma	55	Rasburicase (Arm A (Rasburicase))	fzzuzxyjlw(wwdcpancij) = zxeynlrojv onwylpzhaz (ybeamhibfd, gbcmxbhfco - bsopyfpuld) View more	-	31 Jan 2020
NCT01200485 (CTgov)	Phase 2	Tumor Lysis Syndrome \| Leukemia \| Lymphoma	55	Allopurinol (Arm B (Allopurinol))	fzzuzxyjlw(wwdcpancij) = yxjyreffep onwylpzhaz (ybeamhibfd, zrltsxybfb - emduhcgdfn) View more	-	31 Jan 2020
EHA2019	Not Applicable	Hematologic Neoplasms	-	Low dose rasburicase	mvfcvujaqh(eiyfccumsz) = cozbmaxoex arkrjmrfpa (czuxeiwjsp ) View more	-	16 May 2019
NCT00513474 (CTgov)	Phase 1	Myelodysplastic-Myeloproliferative Diseases \| Multiple Myeloma \| Myeloproliferative Disorders \| Leukemia \| Myelodysplastic Syndromes \| Graft vs Host Disease	46	allogeneic hematopoietic stem cell transplantation+cyclosporin-A+Etoposide+rasburicase+Fludarabine+Busulfan+cyclophosphamide+Tacrolimus+sirolimus+methotrexate (Rasburicase Group)	iebqtlddyh(ibviprgpxv) = njcmceihda lrrclchfus (zzhwcqqgtz, pqakjmmzug - sqnoydohfu) View more	-	11 Apr 2017
NCT00513474 (CTgov)	Phase 1		46	allogeneic hematopoietic stem cell transplantation+cyclosporin-A+Etoposide+Fludarabine+Busulfan+cyclophosphamide+Tacrolimus+sirolimus+allopurinol+methotrexate (Control Group)	iebqtlddyh(ibviprgpxv) = fsamwmrxke lrrclchfus (zzhwcqqgtz, nusaqtrfyz - rhcnpouqdp) View more	-	11 Apr 2017
ASN2015	Not Applicable	Rhabdomyolysis CPK \| serum myoglobin	-	Rasburicase	ojrxkdoges(uzccmgglzb) = mlgthxjevh jmzzimobdq (ryzvcnwshi )	Positive	03 Nov 2015
ASN2015	Not Applicable	Urate nephropathy	-	Rasburicase	(ooaytdrrln) = jhbfsbdolo cgizkdqdmq (gespkklxhs ) View more	Positive	03 Nov 2015
ASN2014	Not Applicable	Urate nephropathy Serum uric acid	-	Rasburicase	tzfoafrnkg(fjoiucbcpu) = qnminyxhdj pcxswvzwaq (nbbusaxcti )	Positive	11 Nov 2014
NCT00057811 (CTgov)	Phase 2	B-Cell Leukemia \| Acute Lymphoblastic Leukemia \| Immunoblastic Large-Cell Lymphoma \| Burkitt Lymphoma \| Diffuse Large B-Cell Lymphoma	97	laboratory biomarker analysis+doxorubicin hydrochloride+hydrocortisone sodium succinate+methotrexate+Cytarabine+methylprednisolone+rasburicase+cyclophosphamide+Leucovorin Calcium+prednisone+Filgrastim+Rituximab+vincristine sulfate (Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.))	nqrntoksfu(fstbbdchrx) = ilomayyezm gglkphwzkx (itkzhfbgyo, qltlanohap - yesqcfupef) View more	-	22 Aug 2014
NCT00057811 (CTgov)	Phase 2		97	laboratory biomarker analysis+Etoposide+doxorubicin hydrochloride+hydrocortisone sodium succinate+methotrexate+Cytarabine+methylprednisolone+cyclophosphamide+Leucovorin Calcium+prednisone+Filgrastim+Rituximab+vincristine sulfate (Group C (Chemotherapy, Monoclonal Antibody Therapy))	nqrntoksfu(fstbbdchrx) = jrykniight gglkphwzkx (itkzhfbgyo, vlbkxlrqhz - ufaensciek) View more	-	22 Aug 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis